Aim to observe the application of MR-Linac for precision radiotherapy of tumours, analyse its therapeutic effect, toxic and side effects,Characteristics of dosimetric parameters etc.
Patients are undergoing or have undergone imaging or treatment at the MR linac;
Age 18-75 years, male or female;
ECOG score 0-2, life expectancy > 6 months;
Patients provide written informed consent.
Contraindications to MRI, such as claustrophobia and metallic or electronic implants incompatible with MRI;
The presence of severe comorbidities that, in the opinion of the investigator, · preclude the toleration or completion of radiotherapy;
Acute inflammatory disease requiring systemic therapy;
The presence of active infectious disease;
The patients will receive or have completed imaging or treatment procedures at MR-Linac, Department of Radiotherapy, Second Affiliated Hospital of Hainan Medical University, age 18-75 years, male or female, ECOG score 0-2, life expectancy \> 6 months.
Cohort
Prospective
MR-Linac
DeviceRadiation therapy with the MR-Linac
overall response rate
The proportion of patients whose tumor volume reduction reached the predetermined value and maintained the minimum time limit requirement was the sum of CR (Complete Response) and PR (Partial Response) proportions.
Progression-Free Survival
The time from the start of treatment until objective tumor Progression or patient all-cause death
Disease Control Rate
The percentage of patients whose cancer shrinks or remains stable over time
Overall survival
Overall survival of participating patients will be obtained from the hospital information systems
Incidence of adverse reactions
Disease-specific toxicity is obtained from the hospital information system. Toxicities are reported according to the Common Terminology Criteria for Adverse Events (CTCAE) dictionary
Click on the lead sponsor to view all of their trials.
